When should cholesterol‑lowering therapy (statin) be discontinued in a patient?

When to Consider Stopping Cholesterol Medicine (Statin Therapy)

Direct Answer

Statins should rarely be discontinued once started, and stopping therapy is associated with worse cardiovascular outcomes and increased mortality—particularly dangerous after acute coronary events. 1, 2, 3, 4

---

Specific Clinical Scenarios Where Discontinuation May Be Considered

1. Age ≥75 Years with Limited Life Expectancy

• Consider stopping statins when functional decline, multimorbidity, frailty, or reduced life expectancy (Class IIb recommendation) make cardiovascular benefit unlikely within 3–5 years 1
• For patients ≥75 years already tolerating high-intensity statins, continuation is reasonable unless the above conditions develop 1
• In secondary prevention (established cardiovascular disease), age alone is not a reason to stop—continue moderate- or high-intensity therapy unless contraindications emerge 1

2. Pregnancy Planning or Pregnancy

• Stop statins 1–2 months before attempting conception (Class I recommendation) 1
• Immediately discontinue if pregnancy is discovered while on statin therapy 1
• Bile acid sequestrants may be considered as alternatives during pregnancy if lipid control is essential 1

3. Severe Statin Intolerance

• Persistent muscle symptoms with CK ≥10× upper limit of normal (ULN): stop statin, monitor CK every 2 weeks, check renal function 1
• Symptomatic myopathy with CK <10× ULN: stop statin, allow symptom resolution, then rechallenge with lower dose or alternate statin 1
• If multiple statins fail due to intolerance, switch to non-statin therapies (ezetimibe, bempedoic acid, PCSK9 inhibitors) rather than abandoning lipid-lowering entirely 1, 5, 6

4. Severe Hepatotoxicity

• ALT/AST ≥3× ULN: reduce dose or temporarily withhold; permanently discontinue only if elevations persist despite dose reduction 1, 5, 6
• Hy's Law criteria (ALT/AST ≥3× ULN + bilirubin ≥2× ULN): immediately and permanently discontinue 5, 6
• Symptomatic hepatotoxicity (jaundice, severe fatigue, right upper quadrant pain): immediately stop statin 5, 6
• Mild elevations <3× ULN are not a reason to stop—continue therapy and recheck in 4–8 weeks 1, 5, 6

5. Dialysis Patients Without Established Cardiovascular Disease

• Statins are not recommended for primary prevention in patients on dialysis (Class III recommendation) 1
• If already on statins when dialysis starts and the patient has established cardiovascular disease, continue therapy 1

6. Decompensated Cirrhosis or Acute Liver Failure

• Statins are contraindicated in decompensated cirrhosis and acute liver failure 5, 6
• Compensated chronic liver disease (including NAFLD, chronic hepatitis B/C, compensated cirrhosis) is not a contraindication—statins may actually improve liver enzymes 5, 6

---

Critical Warnings: When NOT to Stop Statins

Never Stop After Acute Coronary Syndrome

• Discontinuing statins during hospitalization for acute coronary syndrome increases mortality and morbidity (11.9% vs 5.7% event rate, p<0.01) 3, 4
• Patients who stop statins after acute events have worse outcomes than those never prescribed statins, suggesting a harmful rebound phenomenon 2, 3, 4
• Intensify rather than stop: the 2025 ESC/EAS guidelines recommend immediate high-intensity statin + ezetimibe for acute coronary syndrome patients 7, 8

Do Not Stop for Mild Transaminase Elevations

• ALT/AST <3× ULN are not a reason to discontinue—these elevations are clinically insignificant and do not predict hepatotoxicity 1, 5, 6
• Stopping statins for minor enzyme rises removes proven cardiovascular protection without evidence of harm 5, 6

Do Not Stop When LDL-C Reaches Target

• Discontinuing statins after achieving LDL-C goals results in 79% relapse rate within 10 weeks in diabetic patients 9
• Reducing statin dose after reaching target leads to significantly higher follow-up LDL-C and loss of goal attainment 10
• Maintain the effective dose—do not reduce or stop unless absolute contraindication or intolerable adverse effects occur 10

---

Algorithm for Decision-Making

Step 1: Is the patient experiencing an acute coronary syndrome or recent cardiovascular event?
→ Yes: Do not stop; intensify therapy 3, 4, 7, 8
→ No: Proceed to Step 2

Step 2: Is the patient pregnant, planning pregnancy, or breastfeeding?
→ Yes: Stop statin 1–2 months before conception or immediately if pregnant 1
→ No: Proceed to Step 3

Step 3: Does the patient have severe statin intolerance (CK ≥10× ULN with symptoms, or recurrent myopathy despite multiple statin trials)?
→ Yes: Stop current statin; switch to non-statin therapy (ezetimibe, bempedoic acid, PCSK9i) 1, 5
→ No: Proceed to Step 4

Step 4: Does the patient have severe hepatotoxicity (ALT/AST ≥3× ULN persistently, or Hy's Law criteria, or symptomatic liver injury)?
→ Yes: Stop statin; evaluate alternative causes; consider non-statin therapy 1, 5, 6
→ No: Proceed to Step 5

Step 5: Is the patient ≥75 years with functional decline, multimorbidity, frailty, or life expectancy <3–5 years?
→ Yes: Consider stopping in primary prevention only; continue in secondary prevention unless contraindicated 1
→ No: Proceed to Step 6

Step 6: Is the patient on dialysis without established cardiovascular disease?
→ Yes: Stopping is reasonable (Class III recommendation for initiation) 1
→ No: Continue statin therapy

---

Common Pitfalls to Avoid

• Do not stop statins during hospitalization for any acute illness, especially acute coronary syndrome—this dramatically worsens outcomes 3, 4
• Do not reduce or stop statins once LDL-C targets are achieved—this leads to rapid relapse 9, 10
• Do not discontinue for ALT/AST <3× ULN—these mild elevations are not clinically significant 1, 5, 6
• Do not withhold statins from patients with NAFLD or compensated chronic liver disease—they are safe and may improve liver enzymes 5, 6
• Do not assume all muscle symptoms are statin-related—evaluate alternative causes and attempt rechallenge with lower dose or alternate statin before abandoning therapy 1
• Do not stop statins in elderly patients with established cardiovascular disease based on age alone—cardiovascular benefit persists 1

---

Evidence Strength Summary

The strongest evidence against stopping statins comes from:

• Acute coronary syndrome data showing increased mortality with discontinuation (Class I evidence) 3, 4
• 2018 AHA/ACC guidelines (Class IIb) recommending continuation in elderly patients unless frailty/limited life expectancy 1
• Pregnancy guidelines (Class I) mandating discontinuation 1–2 months before conception 1

The evidence base for statin therapy is the most robust compared with any other drug intervention, and discontinuation should be rare and carefully justified 1